ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "HLA antibodies"

  • 2017 American Transplant Congress

    Prediction of Positive Cytotoxic and Flow Crossmatches for Sensitized Wait List Candidates: Comparison of Luminex MFI, C1q and FcR Binding Assays.

    A. Girnita, E. Woodle.

    Surgery, University of Cincinnati, Cincinnati

    Clinical relevance of HLA antibodies identified in solid phase assays includes their ability to generate a positive crossmatch (XM) test, which often precludes transplantation. The…
  • 2017 American Transplant Congress

    Experience with the Bacterial Enzyme IdeS (IgG Endopeptidase) for Desensitization of Highly-HLA Sensitized (HS) Kidney Allograft Recipients.

    S. Jordan,1 J. Choi,1 C. Kjellman,2 L. Winstedt,2 X. Zhang,4 S. Louie,1 A. Kang,1 M. Haas,3 A. Vo.1

    1Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; 2Hansa Medical, Lund, Sweden; 3Dept of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA; 4HLA, Cedars-Sinai Medical Center, Los Angeles, CA

    Donor specific antibodies (DSA) create an impenetrable immunologic barrier to transplantation. Current rx aimed at modification of DSAs are not effective in the most HS…
  • 2017 American Transplant Congress

    Circulating Donor-Specific Memory B Cells (mBc) Discriminates Kidney Transplant Patients with Histological Lesions of ABMR in Absence of Circulating DSA.

    S. Luque,2 M. Lúcia,4 M. Jarque,2 E. Crespo,2 E. Melilli,1 J. Martorell,3 J. Cruzado,1,2 J. Torras,1,2 J. Grinyó,1,2 O. Bestard.1,2

    1Kidney Transplant Unit, Nephrology Department, Bellvitge University Hospital, Barcelona, Catalunya, Spain; 2Experimental Nephrology Laboratory, IDIBELL, Barcelona, Catalunya, Spain; 3Immunogenetics Laboratory, Hospital Clínic, Barcelona, Catalunya, Spain; 4Transplant Immunology, School of Medicine, Stanford

    Chronic (c)ABMR is a main cause of immune-mediated kidney allograft loss. For its diagnosis, specific histological lesions together with presence of circulating donor-specific alloantibodies (DSA)…
  • 2017 American Transplant Congress

    Outcome of Systemic Monitoring of DSA and Protocol Management to Optimize Renal Allograft Outcome in a Single Transplant Center.

    S. Chang,1 I. Mallawaarachchi,2 C. Yip,1 T. Shanahan,3 A. Gundroo,1 A. Dwivedi,2 S. Patel,4 M. Zachariah.1

    1Internal Medicine, University of Buffalo, Buffalo, NY; 2Biomedical Sciences, Texas Tech University, El Paso, TX; 3IMMCO Diagnostics, Buffalo, NY; 4Surgery, University of Buffalo, Buffalo, NY

    Denovo (dn) donor specific antibody (DSA) development has been shown to adversely affect long-term allograft survival. To improve graft outcome for kidney (K) transplant (Tx)…
  • 2017 American Transplant Congress

    Impact of Serum EDTA Treatment on Identification of Unacceptable Antigens for Kidney Transplant Candidates.

    J. Xin, N. Brown, R. Upchurch, J. Weidner, S. Marino.

    Pathology, University of Chicago Medicine, Chicago, IL

    BACKGROUND AND AIMS: The prozone effect is one factor causing false negative reactions in HLA antibody testing. EDTA, which is commonly used to remove this…
  • 2016 American Transplant Congress

    De Novo Anti-HLA DSA Characteristics and Subclinical Antibody Mediated Kidney Allograft Injuries.

    T. Yamamoto, Y. Watarai, A. Takeda, M. Okada, M. Tsujita, T. Hiramitsu, N. Goto, S. Narumi, K. Morozumi, K. Uchida, T. Kobayashi.

    Nagoya daini red cross hospital, Nagoya, Japan.

    Background It has been reported that de novo donor-specific HLA antibody (dn DSA) production is associated with chronic antibody-mediated rejection (CAMR) which leads to poor…
  • 2016 American Transplant Congress

    Anti-HLA Antibody Composition and Outcomes in Pediatric Heart Transplant Recipients with a Positive Cross-Match.

    P. Jindra,1 S. Nicholas,2 J. Chappelle,1 T. Humlicek,2 K. Hosek,2 J. Heinle,2 S. Denfield,2 A. Jeewa,2 R. Kerman,1 W. Dreyer.2

    1Surgery Immune Evaluation Lab, Baylor College of Medicine, Houston, TX; 2Pediatrics, Baylor College of Medicine, Houston, TX.

    Purpose: Utilization of positive (+) cross-match (XM) hearts is tempting when shortages of pediatric donor hearts exist, especially for patients with high pre-transplant panel reactive…
  • 2016 American Transplant Congress

    Optimizing CPRAs for Sensitized Kidney Waitlist Candidates: The Devil Is in the KAS Details.

    J. Houp,1 R. Vega,1 B. Lonze,2 N. Desai,2 R. Montgomery,2 A. Jackson.1

    1Medicine, Johns Hopkins University, Baltimore, MD; 2Surgery, Johns Hopkins University, Baltimore, MD.

    The new kidney allocation system (KAS) has increased transplant rates for highly sensitized candidates. We hypothesized that increasing unacceptable antigens to transition candidates from 80-98%…
  • 2016 American Transplant Congress

    Long Term Outcomes Following Antibody Mediated Rejection (AMR) in Renal Transplant Recipients.

    R. Crew, S. Patel, H. Morris, M. Chiles, L. Ratner.

    Columbia University, New York.

    INTRO: Progress in AMR treatment has improved early graft survival. Since the new kidney allocation system results in more sensitized patients getting transplanted, we expect…
  • 2016 American Transplant Congress

    Dilution of Patient Sera Improves MFI Correlation with Complement Fixation in Solid Phase Assay Assessment.

    C. Castleberry,1 D. Phelan,2 K. Simpson,1 T. Mohanakumar,3 C. Canter.1

    1Pediatric Cardiology, Washington University School of Medicine, St. Louis, MO; 2Histocompatibility Laboratory, Barnes-Jewish Hospital, St. Louis, MO; 3Surgery, Washington University School of Medicine, St. Louis, MO.

    Background: Median Fluorescent Intensity (MFI) by solid phase assays (SPA) has been used to determine risk of donor-recipient reaction prior to transplant. Inconsistency of this…
  • « Previous Page
  • 1
  • …
  • 31
  • 32
  • 33
  • 34
  • 35
  • …
  • 47
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences